Lineage Cell Therapeutics Q3 2024 net loss $3.0M, revenue $3.8M; OpRegen gets RMAT designation

Lineage Cell Therapeutics, Inc.

2024-Q3 EPS reported -$0.08 revenue$6,631,000

Net loss $3.0M ($0.02/sh) vs $7.1M ($0.04/sh) in Q3 2023; revenue $3.8M vs $1.2M.
Cash $32.7M expected to fund operations into Q1 2026.
OpRegen (RG6501) received RMAT designation from FDA for geographic atrophy secondary to AMD.
OPC1 spinal cord injury study start-up activities ongoing; ReSonance preclinical results presented.
Operating expenses $7.6M ($3.2M R&D, $4.4M G&A), down from $7.9M in Q3 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.